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Introduction 
INTRODUCTION
“As a destroyer of mankind, tuberculosis has no equal….”
V A Moore
Tuberculosis, “the captain of all the men of death”, a reemergent 
killer,  is  threatening to assume serious proportions all  over  the world. 
India is  one of  the worst  affected  countries  bears  about  28.4% of the 
entire world’s population.  There are 15 million estimated cases in India 
with 8.8 million new cases, of which 3.9 million cases are smear positive. 
Every year 2.2 million contact tuberculosis and every second an Indian 
over 20 years of age is infected. (RNTCP statistical report, 2005).
Tuberculosis became a problem with the emergence of HIV/AIDS 
pandemic,  because HIV not only reactivates a latent infection but also 
makes the disease more serious and treatment ineffective.  Another factor 
that  has made the situation more grave is the emergence of multidrug 
resistant  tuberculosis  (MDR  TB).   So  serious  is  the  global  threat  of 
tuberculosis WHO in 1993 took the unprecedented step of declaring this 
disease, a global emergency6.  
Extra Pulmonary tuberculosis is increasing worldwide.  The global 
increase is believed to be fuelled by the HIV related immune competence, 
more than 70% of the HIV positive individual with tuberculosis have had 
extra  pulmonary  presentation,  while  its  prevalence  is  15  –  30%  in 
immuno compromised individuals46.
Tuberculosis  of  the  pleura  is  considered  to  be  one  among  the 
severe form of extra pulmonary tuberculosis.   It can occur alone or in 
combination with the pulmonary variety112.
Pleural effusion caused by M. tuberculosis occurs in approximately 
30% of  patients  with  tuberculosis46.  One  of  the  common  sequelae  of 
pleural  effusion  is  residual  pleural  thickening.  Fibrothorax,  Empyema 
thoracis,  Empyema  necessitans,  pneumothorax,  and  pyopneumothorax 
are other complications25,120.
The  non-availability  of  technically  simple,  reliable,  rapid  and 
reproducible  test  often  makes  the  diagnosis  difficult.   The  traditional 
method of Mycobacterial culture, though considered as a gold standard is 
less  sensitive  and  takes  several  weeks  to  become  positive.   In 
paucibacillary situations like tuberculous pleurisy even the sensitivity of 
smear examination is very low.
In circumstances where smear and culture are negative but when 
the  clinical  suspicion  is  high  and  corroborative  evidences  such  as 
radiological and biochemical analysis of pleural fluid are apparent ,  other 
reliable tests with increased sensitivity may be needed. In the scenario of 
global  resurgence  of  tuberculosis  a  rapid,  sensitive  and  cost  effective 
diagnostic  test  would  aid  in  early  diagnosis  and  prompt  initiation  of 
appropriate treatment  there by limiting the spread of infection especially 
in the developing countries where vast majority of cases occur. 
PCR  is  the  rapid  and  sensitive  method  when  compared  to  the 
traditional  methods.   It  can  amplify  even  a  single  bacilli  present 
paucibacillary TPE.  But the expensive laboratory set up and the non-
availability of PCR at peripheral centers are the demerits  of PCR as a 
routine diagnostic test.
Serological  studies  provide  information  concerning  events  of 
humoral immunity following Mycobacterial infection and also offer more 
pragmatic  perspectives  i.e.,  the  possible  early  and  rapid  diagnosis  of 
tuberculosis.  ELISA  techniques  using  various  Mycobacterial  antigens 
have been employed for the serodiagnosis of tuberculosis. A60 antigen 
complex  appeared  to  be  a  dominant  antigen  during  human  infections. 
Several of its characteristics such as heat stability and immunodominance 
make it as a perfect antigen candidate to be used in a diagnostic system23. 
The present study was undertaken to explore the usefulness of this  novel 
antigen,  A 60 antigen complex in the diagnostically  difficult  group of 
extra pulmonary tuberculosis, the tuberculous pleural effusion.
Aims and 
Objectives
AIMS AND OBJECTIVES
1. Isolation  of  Mycobacterium  tuberculosis  in  Tuberculous  pleural 
effusion employing conventional bacteriological methods.
2. Identification  of  Mycobacteria  employing  standard  phenotypic 
methods.
3. Species  level  confirmation  employing  high  performance  liquid 
chromatography.
4. Identification of Mycobacteria employing molecular methods such 
as PCR.
5. Performing  drug  susceptibility  on  the  isolates  confirmed  as 
Mycobacterium tuberculosis.
6. Screening of the study subjects for the presence of HIV infection.
7. To evaluate the diagnostic potential of the A60 antigen complex by 
ELISA in Tuberculous pleural effusion patients.
Review of 
Literature 
REVIEW OF LITERATURE
3.1.TUBERCULOSIS
Definition:
Tuberculosis  is  a  chronic  necrotizing  bacterial  infection  with  a 
wide  variety  of  manifestations  caused  by  Mycobacterium tuberculosis 
complex.  Although, tuberculosis can affect any organ of the body, the 
lung is virtually always the portal of entry120.
History:
Tuberculosis must have been a scourge since mankind existed; as 
reports of this dreadful disease are recorded in the vedas and it was called 
‘rajayakshma’  (meaning wasting disease). Hippocrates called the disease 
“pthisis’, a Greek word which meant,  “to consume” (460 – 377 B.C.). 
Evidence of tuberculosis lesions of bone has also been found in Egyptian 
mummies (3400 B.C.).
J.L. Schonlein, is credited to have name the disease tuberculosis 
(Latin Word: Tubercula) which means “a small lump”.  Oliver Wendell 
Holmes referred to the disease as “white plague”.  Tuberculosis has been 
ever present and is resurging with a Vengeance.
Robert  Koch  first  identified  the  tubercle  bacilli  in  1882.   He 
succeeded in cultivating the bacillus on inspissated serum and transmitted 
the disease to many animals of different species by inoculation with pure 
cultures of the bacillus.  This became the basis of “Koch’s Postulates”. 
Mycobacteria are not readily stained by the Gram method as the 
high lipid content  of  the cell  wall.   Once  stained,  they are  not  easily 
decolourized, this resistance to decolourization is called “acid fastness”. 
In  1882,  Robert  Koch  stained  the  tubercle  bacilli  with  hot  methylene 
blue.  Ehrlich discovered the “acid fast” property of the bacteria in 1882 
and stained the bacilli with hot fuchsin in the presence of aniline oil as a 
mordant.  In 1883 Ziehl changed the mordant to phenol and Neelsen in 
1884 combined the dye and mordant to form carbol fuchsin.  This acid 
fast staining technique is known as the “Ziehl – Neelsen Method”.
Cold Staining technique (kinyoun) as well as the use of fluorescent 
dyes to visualize the Mycobacteria have also been developed.  In 1885 
Nocard isolated the avian form of the tubercle bacilli.   In 1889 Smith 
described the bovine variety.
Etiological agent:
Mycobacterium  is  currently  the  only  genus  in  the  family 
Mycobacteriaceae, order Actinomycetales130.  The minimum standards for 
including a species in this genus are :
• Acid – alcohol fastness.
• The presence of Mycolic acids containing 60 – 90 carbon atoms.
• G + C content of the DNA of 61 – 71 mol% (Levy - Frebault and 
protaels 1992).
Mycobacteria are straight or slightly cured rods about 0.2 - 0.6 X 
1.0 – 10 µm (Wayne and kubica 1986) non-motile, non-sporing, aerobic 
or  microaerophilic.   Colony  morphology  varies  among  the  species,  
M.  tuberculosis  forms  ‘eugonic’  growth  with  rough,  tough  and  buff 
colonies while M. bovis is ‘dysgonic’ with smooth, moist, white colonies 
which break up easily when touched.  NTM forms colonies which are non 
pigmented  (non  Photochromogens)  to  pigmented  (Yellow  to  orange, 
rarely  pink)  some  species  require  light  to  form  pigment 
(Photochromogens) while others produce pigment  either in the light or in 
the  dark  (Scotochromogens)  (Timpe  and  Runyon  1954).  Nutritional 
requirement and temperature range vary considerably.
M. Tuberculosis Complex:
Tuberculosis  of  man  and animals  is  caused by a  group of  very 
closely related species forming M. Tuberculosis complex130. They are
• M. tuberculosis – the human tubercle bacillus
• M. bovis – the bovine tubercle bacillus
• M. microti – the vole tubercle bacillus
• M. africanum – strains of human origin occurring in Africa
• M.  canettii  –  a  new  taxon,  variant  of  M.  tuberculosis 
characterized by smooth colonies (Van Scolingen 1997 Pfyffer 
1998, Mittgen 2002 et al;)
Transmission:
The  tubercle  bacilli  are  commonly  discharged  as  aerosols  of 
pulmonary secretion and are transmitted in air born droplet nuclei (1 to 
10 µm)58.  One bout of cough produces 3,000 droplet nuclei and these can 
stay in the air for a long period of time.   The development of disease 
depends upon the size of the inoculum, duration of exposure, infectivity 
of the Mycobacterial strain and immune status of the host.
Epidemiology:    
Global  forecast  of  tuberculosis  during  1990 –  2000 shows 10.2 
million new cases of tuberculosis occurred world wide in addition to the 
8.22 million existing cases which includes 42% in the South East Asia, 
24% in the Western Pacific region, 14% in the Sub Saharan Africa, 9% in 
the  Europe,  7%  in  the  American  region  and  4%  in  the  Eastern 
Mediterranean region, 75% of tuberculosis cases in developing countries 
are in the productive age group (15-50 Yrs)98.  The disease infects 1% of 
the world’s population each year.
Epidemiological Indices:
About  40%  of  the  Indian  population  are  infected  with  TB. 
Incidence of tuberculosis is about 1.5 per 1,000 populations per year.   It 
increases with age and is more common in males.   The prevalence of 
bacteriologically confirmed disease was 4 cases per 1,000 populations.
3.2. NON TUBERCULOUS MYCOBACTERIA:
Mycobacteria, other than human or bovine tubercle bacilli which 
may  occasionally  cause  human  infection,  have  been  called  non 
tuberculous  Mycobacteria  (NTM).  NTM  infections  become  more 
prevalent in relation to the AIDS pandemic(Brown – Elliott et al; 2002).  
Global Forecast of tuberculosis by WHO report 1997
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It  can  cause  pulmonary  infections  in  the  immuno  compromised  hosts 
(Rigsby  and  Curtis  1994).  NTM  rarely  cause  Tuberculous  pleural 
effusion  but  cases  have  been  reported  caused  by  M.  kansasii73,  M. 
gordonae122 and  M. intracellulare48.
3.3.EXTRA PULMONARY TUBERCULOSIS:
Although  virtually  all  organs  may  get  affected,  the  order  of 
frequency of involvement are the Lymph nodes, Pleura, Bone & Joints, 
Genitourinary tract, Miliary, Meninges and peritoneum118.
TUBERCULOUS PLEURAL EFFUSION:    
Definition:
Accumulation of significant amount of fluid in the pleural cavity is 
called  “Pleural  Effusion”.   Normally  this  means  serous  effusion 
(Exudate).  No pleural effusion can be detected in most of the healthy 
individual although about 15ml may be found in 10% of the population. 
Atleast 300 – 500 ml of fluid must be present in the pleural cavity to be 
detected clinically as well as radiologically.   
Distribution of  tuberculosis cases by anatomical site in HIV – negative patients.  
PTB - Pulmonary tuberculosis, EPTB – Extra pulmonary tuberculosis, GUTB – Genitourinary tuberculosis, MTB – Miliary 
tuberculosis, TBM – Tuberculosis meningitis, ABD – Abdominal tuberculosis, LNTB  - Lymph node tuberculosis. 
(Source : S.K. Sharma & A. Mohan et. al., 2004)
Distribution of  tuberculosis cases by anatomical site in HIV – positive patients.  
PTB - Pulmonary tuberculosis, EPTB – Extra pulmonary tuberculosis, LNTB  - Lymph node tuberculosis. 
(Source : S.K. Sharma & A. Mohan et. al., 2004)
Pathophysiology:
Normally protein free fluid flows from the systemic capillaries in 
the parietal pleura to the pleural space and then to pulmonary capillaries 
in the visceral pleura (amount of fluid is upto 500ml/hr)3.
Protein Exchange: 
Normally pleural fluid contains approximately 1.5g/100ml and this 
protein increases with inflammation.  If protein accumulates, the colloid 
osmotic pressure of the pleural fluid increases and the pressure gradient 
favours the movement of fluid  from both pleural layers into the pleural 
space76.
Pathogenesis:
Classically Tuberculous pleural effusion was described in children 
and  young  adults  who  do  not  have  an  apparent  pulmonary  lesion. 
However as many as 50% now occurs in conjunction with pulmonary 
tuberculosis120.  The pleural infection is always secondary to tuberculosis 
elsewhere, normally in the lung or mediastinal lymph node, reaching the 
pleura by direct extension (rupture of sub pleural focus),  by lymphatic 
spread  or  by  haematogenous  dissemination125.   Because  the  tubercle 
bacilli are found to be very few in effusions, the severe pleural reaction 
may be due to hypersensitivity to the pleural tissues, which develop after 
primary tuberculosis infection81,9.
Diagnosis of Tuberculous Pleural Effusion:
Diagnosis of TPE is usually based on clinical signs and symptoms 
and radiography.  In addition demonstration of Mycobacteria in pleural 
fluid remains the gold standard method.
Clinical Diagnosis: 
TPE most often manifests as an acute illness with complaints of 
chest  pain  (Pleuritic  in  nature),  non  productive  cough  and  dyspnoea. 
Other  constitutional  symptoms  includes  fever  (Low  grade),  loss  of 
appetite, loss of weight, haemoptysis and clubbing15.
Clinical signs includes fullness and diminished movement of the 
chest,  stony  dull  note  on  percussion,  markedly  diminished  or  absent 
breath sounds.   Mediastinal  shift  & tracheal  shift  to  the opposite  side 
noted in massive effusion.
Radiological Diagnosis: 
The  chest  radiography  usually  demonstrates  a  unilateral  pleural 
effusion  and  is  usually  small  to  moderate  in  size.   Bilateral  pleural 
effusion occurs in <10% of cases and indicates Miliary Tuberculosis.  A 
parenchymal  lesion  may  be  seen  in  30  –  50%  of  cases1,110,45.   Ultra 
sonography12 and  C.T.  scan61 are  useful  in  the  diagnosis  of  encysted 
effusion (In India, tuberculosis is the most  common cause of encysted 
effusion).
Laboratory Diagnosis:
This can be broadly divided into 
(1) Demonstration and isolation of Mycobacterium tuberculosis.
(2) Identification and typing of M. tuberculosis.           
(3) Demonstration  of  host’s  response  to  exposure  to  M. 
tuberculosis.
Sputum Smear Examination:
Yield of sputum examination in a patient with pleural effusion is 
quite high if underlying lung parenchymal lesion is present.  Even in the 
absence  of  underlying  lung  infiltrates  sputum  examination  may  be 
positive in 4 – 11% of patients with tuberculous pleural effusion13,30,109.
Composition of Pleural Fluid78:        
Normal Tuberculosis
Volume < 15ml >300 – 500 ml
Cell/mm3 100 – 500 500 – 2,500
Mesothelial Cells 3   – 70% Absent
Lymphocytes 30 – 75% >90%
Granulocytes 10% Early stages
Glucose Plasma level > 60mg/dl
LDH < 50% plasma 
level
> 200 IU
PH ≥ Plasma > 7.3
Protein 1 – 2 g/dl > 3 g/dl
ADA ---- 70 IU/L.
Protein pleural fluid/serum ratio > 0.5
LDH Pleural fluid / serum ratio > 0.680,81
STAINING METHODS:
(1) Ziehl – Neelsen Staining   (ZN)
Microscopy  provides  a  simple,  sensitive  and  rapid  means  of 
detecting  M.  tuberculosis  but  in  paucibacillary  conditions  ZN stain  is 
positive only if number of AFB is more than 10,000/ml of specimen.
SPECIAL STAINING FOR AFB:
Fluorescent Microscopy113
Auramine dye is a fluorochrome, which can be raised to a higher 
energy level after absorbing ultraviolet light.  When the dye molecules 
return to their normal lower energy state they release excess energy in the 
form of visible (fluorescent) light.  Auramine requires   blue   excitations 
light,   exciter  filters  that  select for  light in the 450 – 490  λ wavelength 
range and a barrier filter for 515λ. Brightly fluorescent bacilli will appear 
yellow against  a  dark background17.   Its  sensitivity  and specificity  are 
fairly similar to ZN microscopy113.
Mycobacterial Culture:
For  detection  of  Mycobacteria  in  clinical  specimens  the  current 
“gold standard” consists of a combination of solid and liquid media. The 
specimen  after  processing  may  be  inoculated  into  Egg  based  solid 
medium (Lowenstein  – Jensen Medium)  and Middle  brook 7H9 broth 
medium.   In  detecting  as  few  as  10¹  -  10²  viable  organisms/ml  of 
specimen, culture is more sensitive than smear.  About 4 – 8 weeks may 
be  required  before  the  growth is  detected.   M.  Tuberculosis  produces 
eugonic buff, rough and tough colonies.
DRUG SUSCEPTIBILITY TESTS:
Three general methods26,62: 
• The Absolute concentration Method: It involves standard inoculum 
on media containing graded concentration of drugs and resistance is 
expressed in terms of MIC – minimum inhibitory concentration.
• The Resistance Ratio Method: Compares the growth of known strain 
and test strain in various dilutions of drug media and resistance is 
expressed in terms of ratio of test strain / standard strain.
•  Proportion Method:  This method enables precise estimation of the 
proportion of the bacilli resistant to a given drug.  If  > 1% of strains 
show resistance compared to control at a critical concentration, the 
strain is considered as resistant.
• The proportion of bacilli resistant to a given drug is then determined 
by  expressing  the  resistant  portion  as  a  percentage  of  the  total 
population tested.
3.4.IDENTIFICATION  AND  TYPING  METHODS  OF 
MYCOBACTERIA:
 Typing Methods of Mycobacterium Tuberculosis:
The traditional methods of identification of Mycobacteria based on 
morphological  and  biochemical  properties.   The  current  identification 
scheme mainly relies on molecular methods along with phenotypic tests.
Phenotyping of M. Tuberculosis:
Phenotypic  tests  include  determination  of  preferential  growth, 
temperature, pigmentation, photoreactivity and colony morphology.    
Tests M. Tuberculosis Others
Growth Rate Slow Slow / Rapid
Temp. Requirement 35°c – 37°c 25°c – 37°c
Pigmentation Absent Present / absent
Niacin Positive Mostly negative
Stability of catalase at 68°c Negative Positive
Growth PNB Media Negative Positive
Identification of NTM:
Non-Tuberculous Mycobacteria are usually preliminarily identified 
by traits  such as growth rate and pigmentation according to Runyon’s 
criteria (Runyon 1959).
Runyon’s Classification106:
Runyon 
Group
Growth 
Rate
Pigmentation Typical Members
I Slow
(> = 5 
Days)
Photochromogenic 
(Yellow or Orange 
pigment after 
exposure to light)
M. kansasii
M. marinum
II Slow
(> = 5 
Days)
Scotochromogenic 
(Yellow or Orange 
pigment in the dark)
M. scrofulaceum.
III Slow
(> = 5 
Days)
Non chromogenic 
(no pigment in the 
dark or in the light )
M. avium
M. intra cellulare
IV Rapid 
(< = 4 days)
Variable M. fortuitum 
complex
M. smegematis
M. phelei
Biochemical Tests:
The most useful biochemical tests for the precise characterization 
of species  with in Mycobacterium tuberculosis complex are the niacin 
production,   thermostable  catalase  at  68°c,  aryl  sulphatase,  nitrate 
reductase and phosphatase activity.
Mycolic acid analysis (HPLC):
Mycolic acids are present in all Mycobacterium. Their composition 
is constant for all strains of a given species and varies from species to 
species (Minnikin et al; 1980; Daff’e et al; 1983). A High performance 
liquid  chromatography  method  (HPLC)  for  analysis  of  Mycolic  acid 
esters has been standardized and demonstrated to be a rapid and reliable 
method for identification of many Mycobacterial species.14,22,52,128,129.
MOLECULAR TYPING OF M. TUBERCULOSIS: 
PCR strategy targeting IS 6110.
Detection  of  Mycobacterial  DNA by PCR has  the advantage of 
increased  sensitivity  and specificity.   It  has  been suggested  that  those 
systems that amplify DNA sequences present in multiple copies are more 
sensitive than those that amplify targets present in a single copy.  PCR 
using the IS6110 repetitive sequence as a probe is considered the gold 
standard for typing M. tuberculosis.   IS 6110 is a 355 – bp repetitive 
insertion sequence that displays variability both in the copy number (from 
0 to 25) and chromosomal position130.  This repetitive target increases the 
sensitivity of assay allowing detection of smaller number of bacilli.
Serodiagnosis of M. Tuberculosis: 
M.  Tuberculosis  is  an  intra  cellular  pathogen  that  evokes  both 
cellular and humoral immune response.  Eventhough it is the former that 
determines the outcome of an infection, it  is the later which is mainly 
used in diagnostic purposes.
  Cellular Immune response and delayed hypersensitivity reaction:
CMI can be defined as a beneficial host response characterized by 
an expanded population of specific T Lymphocytes that in the presence of 
microbial antigens produces cytokines locally.  These cytokines attract 
macrophages from the blood stream and activate them.  Tumour Necrosis 
Factor - α and interferon γ  are major macrophage activating cytokines21. 
Interferon  γ  (IFN  –  γ )  also  induces  interleukin  –  2  receptors  in 
macrophages107.   Activated  macrophage  produce  reactive  oxygen  & 
nitrogen intermediates, lysosomal enzymes and other factors that kill and 
digest tubercle bacilli.
HUMORAL IMMUNE RESPONSE:       
The cell wall of Mycobacterium:
Mycobacteria have a complex outer envelope composed of several 
distinct layers (Brennan and Draper 1994). Inner most layer is the plasma 
membrane  inserted  into  it  are  proteins,  mannosides  and 
lipoarabinomannan. 
Next  is  the  peptidoglycan  (murein)  layer  formed  by  complex 
network  of  polysaccharide  chains  cross-linked  by  tetrapeptide  chains 
containing  aminoacids.   A  prominent  feature  of  the  outer  surface  of 
Mycobacteria is its high lipid content which accounts for upto 60% of the 
cell wall weight, composed of glycolipids associated with the long chain 
fatty  acids  termed  Mycolic  acid.   Proteins  are  found  throughout  the 
various layers.
A60 Antigen Complex:
A60 antigen complex is a thermo stable macromolecular antigen 
(TMA) found in the cytosol of Mycobacteria.  This complex is composed 
of  roughly  3
1  proteins,  3
1  carbohydrates  and 3
1 lipids,  exact 
proportions  being  dependent  on  culture  stages23,50.   Researchers  also 
determined that the peptide fraction of A60 contains approximately 30 
distinct bands in the range 20 – 80 kDa as separated by the SDS page 
method47.  The A60 antigen complex is composed of about 3 proteinic 
epitopes  of  which  8  were  identified  by  monoclonal  antibodies 
(Lipoarabinomannan, a glycolipid and proteins of 65,40,38,35,19 and 14 
kDa).   
Species Distribution of A60 Antigen:
A60 antigen complex extracted from M. bovis is genus specific. 
A60 from M. bovis and M. tuberculosis were 98% homologous.  
Humoral Immune Response to A60 antigen complex:
The  humoral  response  elicited  by  the  A60 antigen complex  are 
directed against its protein components (Galot and Wene 1994).  During 
human disease about 90% of the antibody detected were directed against 
Antigen 60.  A60 thus appeared to be a dominant antigen during human 
diseases.  In addition it has been demonstrated that 2 microgram of A60 
induces the same cellular reaction as 5 units of PPD.  
3.5.MANAGEMENT OF TUBERCULOUS PLEURAL EFFUSION:
According  to  Revised  National  Tuberculosis  Control  Program 
(RNTCP),  short  course chemotherapy based on two months of 3 or  4 
drugs followed by 2 drugs for the next 4 months have been found to be 
highly effective in patients with Tuberculous pleural effusion.  The WHO 
is  now  implementing  the  Directly  Observed  Treatment  Short  Course 
(DOTS) in places with a high incidence of tuberculosis88,97.  By ensuring 
cure, this strategy aims at reducing the number of infectious cases in the 
community  and  also  preventing  the  emergence  of  drug  resistance. 
Fluoroquinolones  particularly  ofloxacin  has  good  penetration  into  the 
pleural fluid and hence can be used in the management of patients with 
drug resistant Tuberculous effusion145.  Steroids can be used as a adjunct 
to ATT in severely ill patients7.
Materials and 
Methods
MATERIALS AND METHODS
This  study  was  carried  out  at  Department  of  Microbiology, 
Coimbatore  Medical  College,  Coimbatore,  Tamil  Nadu  from  October 
2004 to September 2005.
4.1. STUDY POPULATION: 
All the Patients who were clinically diagnosed as pleural effusion 
got  admitted  during  the  study  period  with  pleural  effusion  in  the 
Department  of  Medicine,  Coimbatore  Medical  College  Hospital, 
Coimbatore were considered for the study. Those patients who fulfilled 
the following inclusion criteria were included as study population 
Inclusion criteria:
1. Radiological  evidence  of  pleural  effusion  with  or  without 
pulmonary infiltrates (Plate I).
2. Ultrasound and C.T scan (Thorax) evidence of pleural effusion.
3. Biochemical analysis of pleural fluid demonstrated straw colured 
fluid,  total  count  more  than  500  cells  /mm3,  lymphocytic 
predominance  (>  80%)  and  pleural  fluid  glucose  more  than  
60 mg/ dl.
105 patients who fulfilled the above criteria were included in the 
study. Among the 105 cases 10 were < 20 years and 95 were >20 years of 
age. 71 were male and 34 were female.
4.2. SAMPLE COLLECTION: 
Pleural Fluid: 
 Under  strict  aseptic  precautions,  about  20ml  of  pleural  fluid  was 
collected and distributed into  four sterile anticoagulated screw capped 
bottles (Plate II).
I First sample was utilized  for biochemical analysis and looked for 
glucose, protein and chloride.
II Second sample was utilized  for cytology and cell count such as 
total count and differential count.
III Third sample was utilized  for bacteriological examination: Grams 
stain, AFB stain, bacterial  Culture and Mycobacterial culture were 
done. 
IV Fourth sample was stored at -20ºc for PCR.
Plate I
Chest Radiograph (Postero anterior view) showing right sided pleural effusion 
(Source : S.K. Sharma, 2004)
Plate II
Pleural Fluid 
Sputum Sample:
Three  consecutive  early  morning  spontaneously  induced sputum 
samples were collected in sterile screw capped bottles.
Serum Sample: 
Under aseptic precautions 5ml of blood sample was collected by 
venepuncture, serum separated, aliquoted and stored -20°c till the time of 
use.
4.3. LABORATORY SAFETY139:
All  the  safety  measures  were  taken  during  sample  collection. 
Sterile,  leak  proof,  unbreakable  and  properly  labeled  containers  were 
used.   A  microbiological  safety  cabinet  (class  1)  open  fronted  with 
exhaust  was  used.   1% Sodium hypochlorite  was  used  as  disinfectant 
solution.   Cleaning  of  the  laboratory  was  done  with  clear  phenolic 
disinfectants  and  the  room  was  periodically  fumigated  with 
formaldehyde.
4.4. PREPARATION OF SPUTUM SMEAR:
Sputum smear preparation and examination were done in the same 
way as described under microscopic examination of pleural fluid. 
SAMPLE PROCESSING:
                                             PLEURAL FLUID
4.5. PLEURAL FLUID ANALYSIS:
Macroscopic Examination:    
Direct Inoculation Decontamination
Inoculate one loopful 
of  pleural  fluid  each 
onto 3 slopes of  L.J. 
medium.  Label these 
as  set  “A”  and 
incubate  at  25ºc, 
37ºc, and 45ºc.
After direct inoculation, centrifuge remaining 
pleural fluid at 3,000g for 15mts.
Decant supernatant carefully
To deposit add 1ml of 5% H2SO4.
Mix well and let stand for 15mts
Fill up bottle with sterile distilled water.
Centrifuge at 3,000g for 15 minutes.
Discard supernatant carefully.
To deposit add 0.2ml sterile distilled water.
Prepare the smear Inoculate one loopful each onto 3 slopes of 
L.J. medium.  Label these as set “B” and 
incubate at 25ºc, 37ºc, and 45ºc
Transfer remaining deposit into one bottle of 
middle brook 7H9 medium and incubate at 
37°C
Then add 0.2ml into 
one bottle  of  middle 
brook  7H9   broth 
and incubate at 37°C
All  the  105  pleural  fluid  samples  collected  from  clinically 
diagnosed cases were macroscopically examined for colour and turbidity 
(clear  or  serosanguinous).  Cytological  examination  and  biochemical 
analysis were also done in all the samples.
MICROSCOPIC EXAMINATION:
Preparation of Smears125:
The slides used for preparation of smears were clean, grease free 
and pre sterilized. The specimen number was marked on the slide using a 
diamond pencil. A separate new slide was used for each specimen. By 
using  a  5  mm  internal  diameter  24  SWG  Nichrone  wire  loop,  the 
centrifuged deposit of the specimen was smeared as a uniform layer over 
the slide. Finally the slides were air dried and then heat fixed in the safety 
cabinet.
Modified Ziehl Neelsen Staining Procedure84 : 
1. Placed the slide on a staining rack with the smeared side facing 
up.
2. Flooded entire slide with strong carbol – Fuchsin.
3. Heated the slide slowly until it was steaming for 5mts by using 
intermittent heating.
4. The slide was rinsed in a gentle steam of running water until all 
free stain was washed away.
5. Flooded the slide with acid alcohol mixture, as a decolorizing 
agent for 2 to 3mts.
6. Rinsed the slide thoroughly with water.  Drained excess water 
from the slide.
7. Flooded the slide with methylene blue counter stain for 30 sec.
8. Rinsed the slide thoroughly with water, allowed the smear to air 
dry.   
Recording and Reporting of Results : 
For  Ziehl  –  Neelsen’s  stained  smears,  the  following  semi 
quantitative method of reporting is recommended.
No. Of Acid fast bacilli 
(AFB) Fields Report
No AFB In 100 immersion fields Negative
  1 –   9   AFB In 100 immersion fields Record  exact 
figure
10 – 99  AFB In 100 immersion fields 1 +
  1 – 10  AFB Per  field  (examine  50 
fields)
2 +
     > 10  AFB Per  field  (examine  50 
fields)
3 +
4.6. CULTURE METHODS 4,86:
Preparation of Lowenstein Jensen Medium
Mineral salt solution with malachite green:
 The properly weighed mineral salts were dissolved in about 75ml 
of distilled water by heating.  Added 3ml of glycerol to it  and then made 
up to 150ml with distilled water. Sterilization was done by  autoclaving 
at 121˚c for 30 minutes.
Homogenized whole eggs:
Fresh  hen’s  eggs  not  more  than  7  days  old  were  cleaned  by 
scrubbing thoroughly with hand brush using soap and  water . The eggs 
were  soaked  in  soap  solution  for  30  minutes  ,  rinsed  thoroughly  in 
running water and then again  soaked in 70% ethanol for 15mts.  After 
washing the hands thoroughly the eggs were cracked at the edge of the 
beaker  and  poured  in  to  a  sterile  flask  and  beaten  with  a  sterile 
blender.Homogenized  egg  solution  was  prepared  by  filtering  the  egg 
solution into a measuring jar using sterile funnel and gauze.
Preparation of Complete Medium:   
About  150ml  of  mineral  salt  solution  with malachite  green was 
mixed thoroughly with 250ml of homogenized egg solution. The media 
was then distributed in 6 to 8 ml quantities in sterile universal containers 
and the caps were closed tightly.
Coagulation of Medium:
The  bottles  were  placed  in  a  slanted  position  in  the  inspissator 
(85˚c) for 1 hour to coagulate the medium. They were stored at  room 
temperature for over night and again reinspissated for 30 minutes at 85˚c 
on the next date. Sterility of the media was checked by incubating at 37˚c 
for 24 hours (Plate III). 
Preparation of Middlebrook 7H9 broth Medium:
The properly weighed salts  were dissolved in 450ml of  distilled 
water  by  heating,  if  necessary  and  2ml  of  glycerol  was  added  to  it. 
Sterilization was done by autoclaving at 15 lbs pressure at 121˚c for 10 
minutes.  After  cooling to  45˚c,  one vial  (50ml)  of  Middlebrook ADC 
growth supplement was added aseptically and mixed well. The media was 
then distributed in 5ml amounts in sterile screw capped bottles. Sterility 
was checked by over night incubation at 37˚c (Plate IV).  
Plate III
Lowenstein Jenen  Medium
Plate IV
Middle Brooke 7H9 Medium
4.7.INOCULATION:
A loopful of centrifuged sediments of the specimen was inoculated 
over the middle surface of the medium by using a 5mm loop.
4.8. INCUBATION OF CULTURE:
All cultures were incubated at 25°c, 37°c and 45°c.
4.9. CULTURE EXAMINATION:
The cultures were examined weekly to detect any rough, buff and 
tough (cauliflower like growth) colonies. If growth was present, it was 
reported and send for further identification. If no growth, incubation was 
continued till 8 weeks and reported as negative. 
4.10. CULTURE REPORTS: 
Culture reports recorded were qualitative (Positive or negative) as 
well as quantitative (number of colonies isolated).
Reading Report
No growth Negative
1   -    19  colonies Positive (Number of colonies)
20 -  100  colonies Positive (1+)
> 100  discrete colonies Positive (2+)
Confluent growth Positive (3+)
Contaminated Contaminated
4.11. DRUG SUSCEPTIBILITY TEST26
The absolute concentration Method:
A standardized  inoculum grown on drug  free  media  and  media 
containing  graded  concentration  of  the  drugs  were  tested.   Several 
concentration of each drug was tested and resistance was expressed in 
terms of the lowest  concentration of the drug that inhibits growth i.e., 
minimum inhibitory concentration.
Drug free LJ medium:
Drug free LJ fluid medium was prepared as mentioned before. The 
graded concentration of various drugs were added as follows and then 
inspissated to coagulate the medium (Plate V).
STREPTOMYCIN - S.
Stock solution: 
250  mg  of  streptomycin  sulphate  in  20ml  of  distilled  water. 
(10,000 µg/ml)
Working solution:
4 ml of 10,000µg/ml + 16ml water = 2,000 µg/ml.  
 1 ml of 2,000µg/ml + 19ml water  = 100 µg/ml.
Media preparation:
ML of stock
µg ml
LJ Medium
(ML)
Final Concentration 
(µg/ml)
2.0 100 100 2
4.0 100 100 4
2.4 2000 600 8
4.8 2000 600 16
9.6 2000 600 32
3.84 10000 600 64
ISONIAZID:  (INH)
Stock solution:
200mg Isoniazid in 20ml distilled water (10,000 µg/ml). Sterilized 
by membrane filtration.
Working Solution:
ML of Stock (µg/ml) Water (ml) µg/ml
1 ml of   10,000 9 1,000
2 ml of   1,000 18 100
1 ml of   100 19 5
2 ml of   5 8 1
Media preparation:
Stock (µg/ml) LJ medium (ml) µg/ml
2.5 ml of       1 µg/ml 100 0.025
5ml    of        1 µg/ml 100 0.05
2ml    of        5 µg/ml 100 0.1
1.2ml of    100 µg/ml 600 0.2
6ml    of    100 µg/ml 600 1.0
3ml    of 1,000 µg/ml 600 5.0
RIFAMPICIN (R)
Stock solution:
200mg rifampicin in 20ml of dimethyl formamide (10,000 µg/ml).
Working solution:
4 ml of 10,000 µg/ml + 16ml water = 2,000 µg/ml
2 ml of 2,000   µg/ml + 18ml water =    200 µg/ml
Media preparation:
Stock (µg/ml) LJ medium (ml) µg/ml
2.0   ml of       200 µg/ml 100 4
4      ml of       200 µg/ml 100 8
8      ml of       200 µg/ml 100 16
9.6   ml of    2,000 µg/ml 600 32
3.84 ml of  10,000 µg/ml 600 64
7.68 ml of  10,000 µg/ml 600 128
ETHAMBUTOL (E)
Stock solution:
270mg  Ethambutol  in  20ml  of  distilled  water  (10,000  µg/ml). 
Sterilized by membrane filtration.
Working solution:
Stock (µg/ml) Water (ml) µg/ml
  2 ml of 10,000 18 1,000
10 ml of 1,000 10 500
  1 ml of 5,00 9 50
Media preparation:
Stock (µg/ml) LJ medium (ml) µg/ml
1.0 ml of      500 µg/ml 100 0.5
2    ml of      500 µg/ml 100 1.0
2.4 ml of      500 µg/ml 600 2.0
4.8 ml of      500 µg/ml 600 4.0
4.8 ml of   1,000 µg/ml 600 8.0
Inoculation:
A bacterial suspension was prepared by adding approximately 4mg 
moist weight of a representative sample of the bacterial mass visualized, 
(as ⅔ loopful of 3mm internal diameter 24 SWG wire loop) into 0.2ml of 
sterile distilled water in 7ml Bijou bottle containing twelve 2 to 3 mm 
glass  beads.  Shake  the  bottle  for  1  minute  to  produce  a  uniform 
suspension, then add 0.8ml of sterile water and again  shake the bottle. 
This suspension contains approximately 4 mg/ml of the organism.
Using  a  3mm  external  diameter  27  SWG  nichrome  wire  loop, 
inoculated one loopful of this suspension on each slope of the sensitivity 
test media. Setup three control drug free media (1 for control and 2 for 
catalase & niacin tests).  Tested the standard sensitive strain   H37 Rv 
with each batch of test.  Incubated all slopes at 37˚c except one control 
drug free slope, which was incubated at 25˚c.
Reading:
  The inoculated slopes were examined for growth after 28 days of 
incubation.  Growth is defined as the presence of 20 or more colonies on 
a slope.
Interpretation of tests:
The lowest concentration of the drug that inhibits growth (MIC) 
was recorded.  The ratio of the MIC of the test train to the MIC of the 
strain  H37  Rv  set  up  with  each  batch  of  tests  is  referred  to  as  the 
resistance ratio (RR).
Definition of resistance 
Drug Level of resistance
Streptomycin Resistance ratio of drug conc 8µg/ml or more
Isoniazid   MIC of drug conc        5     µg/ml or more
Rifampicin   MIC of drug conc      128   µg/ml or more
Ethambutol   MIC of drug conc         8    µg/ml or more
  
4.12. IDENTIFICATION TESTS:
1. Susceptibility to p. nitro benzoic acid (PNB).
2. Niacin Test.
3. Catalase activity at 68˚c /pH 7.
1.  SUSCEPTIBILITY TO P. NITRO BENZOIC ACID
Stock solution
One gm of PNB was dissolved in 40ml of dimethyl formamide and 
mixed thoroughly which was added to entire quantity  of  2liters  of  LJ 
fluid giving a final concentration of 500mg/l.  The media was distributed 
and inspissated.
Procedure:
A loopful of bacterial suspension was inoculated on one slope of 
LJ medium without drug and 1 slope of LJ medium containing PNB at a 
conc. of 500 mg/l and incubated at 37˚c and the reading were taken after 
28 days. 
Interpretation:
M. Tuberculosis does not grow on PNB medium.
2.  NIACIN TEST138
Reagents:
1. O. Toludine 1.5%
2. Cyanogens Bromide solution 10%.
Procedure:
The positive culture tube was taken and autoclaved at 120˚c for 30 
minutes for the extraction of Niacin.  0.25ml of extract was taken and 
added to solution of 0.25ml of O. toludine and 0.25ml of 10% cyanogens 
bromide  and  mixed  well  in  a  screw  capped  test  tube.  Observed  the 
solution for the formation of pink color (positive) within 5 minutes.
Interpretation
M. tuberculosis showed positive Niacin test (Plate VI).
Plate V
Drug susceptibility test 
Plate VI
M. tuberculosis showing positive Niacin Test  
Plate VII
M. tuberculosis showing negative catalse at 68ºC
Plate VIII
High performance Liquid chromatography 
3.  CATALASE TEST67:
Reagent:
1. 0.067M phosphate buffer solution, pH7.0 
Na2H Po4 anhydrous 9.47g.  
      Distilled water 1 litre.
      Dissolved Na2Hpo4 in water to provide 0.067M solution 
(solution 1)
KH2 Po4 9.07g
Distilled water 1 litre
Dissolved KH2 Po4 in water to give 0.067M solution (solution 2)
Mixed 61.1 ml of solution 1 with 38.9ml of solution 2.
2.  Hydrogen peroxide 30%
3. Tween80 - 10% .
Procedure:
Added  0.5ml  of  0.067M buffer  to  screw capped  test  tubes  and 
emulsified with a loopful of test culture.  Placed the tubes in a water bath 
at 68˚c for 20 minutes.  After cooling to room temperature added 0.5 ml 
of  freshly  prepared  equal  parts  of  10%  tween80  and  30%  H2O2. 
Observed the formation of bubbles appearing on the surface of the liquid. 
Keep negative tubes for 20 minutes.
Interpretation:  
M. tuberculosis showed catalase negative at 68˚c (Plate VII).
4.13.  HIGH  PERFORMANCE  LIQUID  CHROMATOGRAPHY 
(HPLC)
Principle:
The  objective  of  this  method  is  to  identity  Mycobacteria  by 
analysis  of  Mycolic  acids  using  HPLC.   A  suspension  of  AFB  is 
saponified to cleave the Mycolic acids bound to cell wall.  Mycolic acids 
are then separated by acidification and extraction into chloroform.  After 
conversion to UV absorbing p. bromophenacyl esters the Mycolic acids 
are analyzed on a reverse phase C18 column using HPLC.  A gradient of 
methanol  and  dichloromethane  generated  by  micropressor  controlled 
pumps is used to separate the Mycolic acid esters,  which are detected 
with  a  UV spectrophotometer.   Reproducible  chromatographic  pattern 
containing combination of different diagnostic peaks are formed.  Pattern 
recognition is by visual comparison of sample results with Mycolic acid 
patterns from reference species of known Mycobacteria.
Specimen:
MTB grown on LJ medium, verified by ZN smear.
SAMPLE PREPARATION:
A. Cell harvesting Procedure
0.2ml of saponification reagent  was added to 1 – 2 loopful  of 
growth on LJ medium. Vortex for 20 sec. 
B. Saponification and Extraction:
Autoclaved the mixture at 121˚c, 15 PSI for 1 hour, then added 
0.2 ml  of chloroform & 1.5 ml  of acidification reagent (Conc. 
Hcl), Capped tightly and vortex for 20 sec.  Allowed the layers to 
separate in 20 – 30 sec.  Using a glass Pasteur pipette removed 
the  bottom (chloroform)  layer  (containing  Mycolic  acids)  and 
transferred to a new tube.  Evaporated the chloroform in a water 
bath at 85 - 105˚c.
C. Derivitization to p. bromophenacyl esters:   
Added 0.1 ml KOH & evaporated at 85 - 105˚c.  The sample ws 
cooled and then added 1.0 ml of chloroform followed by 50 µl of 
Derivitization reagent.  Capped & vortex for 30 sec. and  again 
heated at 85 – 105˚c for 20 minutes.
D. Clarification by liquid.  liquid extraction:
The sample was cooled and added 1.0 ml of clarification reagent. 
Vortex  for  20  seconds.   The  bottom  (chloroform)  layer  was 
removed and transferred to a  new tube.
E. Completion and Storage:
            Evaporated to dryness at 85 - 105˚c.  Capped tightly and stored at 
4 - 6˚c in the dark.
F. HPLC Analysis of Mycolic acid:
            Mycolic acids were analyzed on a reverse – phase C18 column 
using  HPLC.   A   gradient  of  methanol  and  dichloromethane 
(methylene   chloride)  generated  by  micro  processor  controlled 
pump was used to  separate the Mycolic acid esters which were 
detected with a UV  spectrophotometer (Plate VIII).  
4.14.  PCR FOR M. TUBERCULOSIS (TARGETING IS 6110)
Protocol:
The  chromosomal  DNA  from  pleural  fluid  was  extracted  by 
enzymatic methods.  A 123bp fragment of the M. tuberculosis specific 
gene amplified by PCR with primers IS 6110.  The most commonly used 
genetic maker is the Mycobacterial insertion element IS 6110.  The target 
is repeated 8 -20 times with in the genome in M. tuberculosis complex. 
This repetitive target increases the sensitivity of assay allowing detection 
of  smaller  number  of  bacilli.   PCR carried  out  in  50µl  of  a  reaction 
mixture, 200 µM of dNTP's, IU Taq polymerase, 20 pmoles of each set of 
primers and 10ng of chromosomal DNA.  Samples are then subjected to 
initial denatnuration at 94ºc for 4 min followed by 35 cycles of 90ºc for 1 
min, 72ºc for 1 min, and a final extension at 72ºc for 10 min to complete 
the elongation of the PCR intermediate products.  PCR products are then 
run on 2% agarose gel containing ethidium bromide and examined for the 
presence of the 123bp and compared with 100bp ladder.
4.15. A60 BASED IMMUNO ASSAY:
ELISA Test procedure:
The ELISA plate with 96 micro wells coated with antigen 60 
from M. bovis which has been provided was taken and the assay was 
arranged.  Separate plates for IgG, IgM and IgA were provided along 
with controls.  The references are ready to use were 2 and 16 u references 
for IgG, 4 U and 16U references for IgA, positive and negative control 
for IgM were added to A1 and B1 corresponding wells (100µl). 100µl of 
1:  100  diluted  serum samples  were  added  to  the  subsequent  wells  in 
order.  Incubated at 37˚c for 1 hour.  After that the wells were washed 
with 1: 20-diluted wash buffer.  Then added 100µl of POD - conjugate 
solution in each well including A1and B1.  Incubated the plates at 37˚c 
for 30 minutes.  Again washed the plates 5 times. Then added 100µl of 
1:10 diluted tetramethylbenzidine (TMB) solution in each well including 
A1 and B1.  Incubated  at  37ºc for 15 minutes  in  the  dark.  Then added 
Plate IX
ELISA test 
Plate X
ELISA Kit
100 µl of stop solution.  Read the ELISA plate absorbance at 450nm in 
ELISA Reader (Plate IX).
Cut off Values:
IgM : Positive > 1.0.
IgA : Positive > 350serounits.
IgG : Positive > 225serounits.
4.16. DETECTION OF HIV IN STUDY SUBJECTS:
Test procedure (Microlisa)
The  ELISA  plate  with  96  micro  wells  coated  with  HIV 
recombinant proteins which has been provided was taken and the assay 
was arranged.  A-1 served as the reagent blank.  From well A-1 all the 
controls were arranged in a horizontal and vertical configuration.  100µl 
of the sample diluent was added to A-1 well as blank.  Then added 100µl 
of  negative  control  in  each  well  numbered  B-1  and  C-1  respectively. 
Added 100µl of positive control in D-1, E-1 and F-1 wells.  Then added 
100µl of each sample diluted in sample diluent (sample 20µl and sample 
diluent  200µl  as  1  :  11)  in  each well,  starting from G-1 well.   Then 
incubated at 37˚c for 30minutes.  After 30 mins washed wells 5 times 
with  working  wash  solution  (25X).   Then  added  100  µl  of  working 
conjugate solution (1: 100 dilution) in each well including A-1. Incubated 
the plates at 37ºc for 30 mins.  Washed the plates again 5 times.  Then 
added 100µl of working substrate solution (1 : 100 dilution) in each well 
including  A-1.  Incubated at room temperature (20˚c to 30˚c) for 30 mins 
in  dark.   Then  added  50µl  of  stop  solution.   Read  the  ELISA  plate 
absorbance at 450 nm with in 30 mins in ELISA reader after blanking 
A-1 well (Plate X). The odd value of 0.458 was obtained. 
Results  
RESULTS
The tests were performed as described in materials and methods. 
The results obtained are as follows.
Table 1
Age and Sex distribution of clinically diagnosed TPE (N = 105).
Age Male Female Total
< 20yrs 6 4 10
20-50yrs 49 25 74
>50yrs 16 5 21
Of the 105 cases, 10 (10%) were <20yrs, 74(70%) were in between 
20-50yrs and 21(20%) are above 50yrs.  Maximum cases were recorded 
in the age group between 20 and 50yrs (Figure 1).  In all the age groups 
the  sex  distribution  was  predominantly  male(71%)  with  a  ratio  of  2:1 
(Figure 2).
All  the patients included in the study were belonging to low socio 
economic status.  20% of them were working in the textile industries and 
10%  of  them  were  residing  in  an  area  close  to  textile  units.   Their 
educational status was poor.  Co morbid conditions like smoking; alcohol, 
diabetes, hypertension and previous exposure to tuberculosis were found in 
48 (46%) (Figure 3) of patients.
Table :2
Categorisation of Patients with predisposing factors (n= 48)
Criteria No of Cases
Smoking 15
Alcohol 10
Previous Exposure to TB 3
Over –Crowding 7
Diabetes 5
Hypertension 5
Other Respiratory illness 3
5.1.  DETAILS OF BACTERIOLOGICAL FINDINGS 
Table 3
Sputum smear examination (N = 105).
Category Number of cases ZN Positive
Unilateral PT with effusion 40 5
Bilateral PT with effusion 10 10
Pleural effusion without 
pulmonary lesion
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Sputum smear examination (N = 105).
Number of cases
ZN Positive
Among the 105 cases, 5 (4.8%) cases were ZN positive in patients 
with unilateral  PT with effusion,  10(9.5%) cases  were ZN positive in 
patients  with  bilateral  PT  with  effusion  and  none  of  the  cases  from 
pleural effusion without pulmonary lesion (Figure 4).
5.2. BACTERIOLOGICAL PROFILE
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minan
ce (80 
to 
90%) 
in 
85% 
of 
cases 
with 
total 
count 
varied 
betwe
en 
500  - 
2000 
cells  / 
mm3. 
Pleura
l  fluid 
protei
n 
ranges 
from 
5  – 
7gm/d
l  and 
glucos
e from 
60  – 
80 
mg/dl.
Gram stain and bacterial cultures of the pleural fluid samples were 
negative.
Table 4
Pleural fluid smear examination (N = 105)
Category Number of cases
Smear positive 4
Smear negative 101
Out  of  the  105 clinically  diagnosed cases,  4  cases  (3.8%) were 
smear  positive  (Plate  XI)  and  the  remaining  101  cases  (96.2%)  were 
smear negative (Figure 5).
Table 5
 Pleural fluid culture examination (N = 105)
Category Number of Cases
Culture Positive 21
Culture Negative 84
Among 105 clinically diagnosed TPE, 21(20%) cases were culture 
positive  (Figure 6).
Table 6
Distribution of culture positive cases (N = 21)
Category Number of cases
Mycobacterium tuberculosis 19
Non Tuberculous mycobacteria 2
Among  the  21  culture  positive  cases,  19  cases  (90%)  were 
Mycobacterium  tuberculosis  and  2  cases  (10%)  were  NTM 
(Scotochromogens) (Plate XIII, XIV). 
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Pleural fluid culture examination (N = 105)
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Table 7
Bacteriological profile of clinically diagnosed TPE (n = 105)
Category Culture Positive
Smear 
positive
Smear 
negative
Mycobacterium tuberculosis 
(19) 19 3 16
Non Tuberculous 
mycobacteria (2) 2 0 2
Culture negative (84) 0 1 83
Among  the  19  culture  positive  M.  tuberculosis  cases,  3  (2.8%) 
were smear positive (Plate XII).  ZN was negative in 2 culture positive 
cases of NTM.  Among the 84 culture negative cases 1 (1%) case was 
smear positive.
Table 8
The drug susceptibility pattern in the culture positive cases (N = 21).
Number 
of culture 
positive 
cases.
Drug conc. for standard sensitivity
Streptomycin
(resistance 
ratio)
Isoniazid
MIC
Rifampicin
MIC
Ethambutol
MIC
PNB 500 
µg/ml
Response
to tests.
17 < 2µg <0.2µg <32µg <2µg Sensitive
Sensitive 
to all 
drugs
4 <2µg >5µg <32µg >8µg Sensitive
Multi 
Drug 
Resistance
Plate XI
Pleural fluid smear showing Acid alcohol fast bacilli 
Plate XII
Pleural fluid growth showing acid fast bacilli  
Plate XIII
L.J. Medium Showing growth of Mycobacterium tuberculosis  
Plate XIV
L.J. Medium Showing growth of Non-tuberculous Mycobacterium 
 Out of the 21 culture positive cases, 17 cases were sensitive to all 
first line drugs indicated by no growth on the medium containing required 
and minimal concentration of drugs.  Four cases were Multi drug resistant 
tuberculosis (Plate XV, XVI). 
Species level confirmation of all positive cultures  were done by 
HPLC (Plate XVII).
 
5.3. RESULTS OF  PCR
Table 9
Category S+C+ S+C- S-C+ S-C-
Number of cases 3 1 16 85
PCR Positive 3 1 16 53
Among the 105 cases, PCR was positive in all culture positive 19 
(18%) cases, PCR was positive in a single smear positive case (1%) and 
in the remaining culture and smear negative cases PCR was positive in 53 
cases (51%) (Figure 7, Plate XVIII).
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Drug susceptibility test showing drug resistance 
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Drug susceptibility test showing drug resistance to Ethionamide 
Plate XVII
Chromatography picture of M. tuberculosis 
 
Plate XVIII
A 123 bp fragment of the M. tb amplified by PCR with primers IS 6110  
Plate XIX
ELISA test to detect IgG antibodies to A60 antigen complex 
Plate XX
ELISA test to detect IgA antibodies to A60 antigen complex 
5.4. RESULTS OF SEROLOGICAL METHODS
Table 10
A60 antibody class Number of positive cases
Percentage of 
positivity
IgG + IgM – IgA - 12 11%
IgG – IgM + IgA - 16 15%
IgG – IgM – IgA + 6 6%
IgG + IgM + IgA - 18 17%
IgG + IgM – IgA + 8 8%
IgG – IgM + IgA + 8 8%
IgG + IgM + IgA + 22 21%
IgG – IgM – IgA - 15 14%
Among the 105 clinically proved cases, IgG alone positive in 60 
(57%) cases  (Plate  XIX),  IgM alone  positive  in  64  (61%) cases,  IgA 
alone positive in 44 (42%) (Plate XX) cases whereas IgM and IgA were 
positive in 78 (75%) cases (Figure 8).
5.5 HIV /TB CO INFECTION
In our study we found out 3 cases were positive for HIV antibody 
by ELISA (Microlisa).
Discussion
DISCUSSION
In the present study all the 105 cases were diagnosed as TPE by 
clinical, radiological and Biochemical analysis of pleural fluid.  The age 
and sex distribution in this study showed, among the 105 TPE cases, 10 
were less than 20 years, and 95 were more than 20 years92.  Among them 
71 were male and 34 were female in the ratio of 2: 1.   30% of them were 
associated with textile industries and 46% of them were associated with 
other risk factors.  All of them belongs to low socio economic status with 
poor  education.   This  shows  that  Tuberculous  pleural  effusion  was 
common among middle  aged men,  for  whom predisposing  factors  are 
common.
The common presenting symptoms were chest pain (75%), cough 
(54%), fever (55%), dyspnoea (48%), constitutional symptoms (21%) and 
with multiple symptoms of chest pain, cough and fever (60%) , fever, loss 
of appetite and loss of weight (15%) and cough with haemoptysis (41%).
CATEGORIES OF PATIENTS:
Among  the  105  clinically  diagnosed  TPE,  50  cases  shows 
concomitant pulmonary findings.  Three cases were proven as pulmonary 
tuberculosis  and  completed  full  course  of  ATT  for  one  year  under 
RNTCP.  25 cases were recently started on ATT on clinical grounds.
Categories of patients with concomitant pulmonary findings:
Category Number
Apical P T with effusion 26
PT with effusion with mediastinal shift 2
Mid and lower lobe infiltration with effusion 5
Pyothorax 4
PT with hydropneumothorax 3
Bilateral PT with unilateral effusion 10
Pleural effusion 55
In  our  study  48%  of  patients  with  TPE  have  concomitant 
pulmonary findings.  Sputum smear examination showed that 15 cases 
(14.3%) were smear positive.  Among the 40 cases of unilateral PT with 
effusion  only  5 (4.8%) were ZN positive whereas  all  the  10 cases  of 
bilateral PT with effusion (9.5%) were smear positive.  Sputum smear 
examination  were  negative  in  all  other  TPE  cases  where  there  is  no 
pulmonary infiltration, even though earlier studies showed that even in 
the absence of underlying lung infiltrates smear was positive in 4 –11% 
cases of TPE13,30,109.  So sputum smear examination is much helpful in the 
diagnosis of pleural effusion only when it is associated  with pulmonary 
infiltrates.
Macroscopic  examination  of  pleural  fluid  was  cleal  and  straw 
coloured in most of the cases but serosanguinous fluid were also obtained 
in few cases of TPE. Neutrophilic predominance were also seen in 10 – 
15% of cases. These could be either due to active inflammation in the 
lung parenchyma with tuberculosis or in the early stages of tuberculosis. 
In aspirates from tuberculous pleural effusion, organisms are rarely 
seen following ZN microscopy because of paucibacillary nature of the 
disease.  In our study we have encountered only 4 (3.8%) ZN positive 
cases.   Among the  four,  3  were  culture  positive  and one  was  culture 
negative.  The culture negative case maybe due to the presence of non-
viable mycobacteria in partially treated patients or due to harsh chemical 
treatment used in decontamination19.
  
Mycobacterial culture, though considered as the “Gold Standard” 
was  positive  only  in  20% of  patients13,43.   The  low sensitivity  of  the 
culture  in the pleural  fluid was  also demonstrated in a  study done by 
Berger and Mejia et. al., who verified that in the pleural fluid cultures, it 
is only possible to detect the presence of the M. tuberculosis in 20 – 30% 
of infected patients13.  In another study done by SK Katiyar and RP Singh 
et. al., culture was positive only in 19.05% of cases. In this study four 
cases of multi drug resistant tuberculosis were found. Another important 
consideration is the occurrence of natural drug resistant mutants.
The results are not surprising considering the fact that the pleural 
effusion in patients with tuberculosis mainly occurs as a result of delayed 
hypersensitivity  reaction  to  Tuberculin  proteins  and  the  presence  of 
bacilli in pleural fluid is not always necessary. Direct examination of 
pleural  fluid and ZN staining requires  bacillary concentration of  more 
than 10,000 /ml and therefore has a low sensitivity.  Although culture is 
more sensitive, it requires a minimum of 10 viable bacilli/ml.
Although, TPE may resolve over a period of several months with 
out treatment, failure to diagnose and treat pleural tuberculosis can result 
in progressive disease and the involvement of other organs in as many as 
65% of patients.  However, treatment based on clinical suspicion rather 
than  on  microbiological  diagnosis  results  in  over  treatment,  delay  in 
accurate diagnosis and potentially greater morbidity.  A remarkable delay 
is frequent in EPTB.
PCR  is  the  rapid  and  sensitive  method  for  the  detection  of 
Mycobacterial DNA in TPE (Nagesh et.al.,  2001).  The PCR protocol 
used in  this  study was based on the amplification  of  a portion of  the 
mycobacterium  tuberculosis  genome  located  in  the  IS  6110  insertion 
sequence.   Thierry  and  collaborators  described  that  this  sequence  is 
repeated approximately 20 times in the genome of mycobacteria and it is 
specific for the M. tuberculosis complex132.
In our study all culture positive and smear positive cases were PCR 
positive.  2 NTM cases were also subjected to PCR but the PCR results 
were  negative  because  the  primers  used  were  specific  for  M. 
Tuberculosis.  Among the 85 culture negative cases PCR was positive in 
53 cases.  PCR was positive overall in 73 cases (70%).  These data are in 
agreement  with  those  obtained  by  Nagesh  et.  al.,  They  reported  a 
sensitivity of 70% and specificity of 100%.
Sensitivity and Specificity of PCR shown in various studies an listed in 
the Table below:
Negative PCR seen in 32 cases may be due either to inhibitors of 
Taq polymerase that are particularly high in pleural fluid or to sampling 
Reference Sensitivity Specificity
S. Nagesh, Jindal Et. Al., 2001 70% 100%
Portillo – Gomez L, Et.Al., 2000 94% 100%
Lazraq R, Guesdon JL Et. Al., 1999 93% 95%
Tan MF, Ng WC Et. Al., 1997 100% 88%
Gunisha P, Medhavan HN Et. Al., 2000 30% 95%
Almeda J, Gaenia A Et. Al., 2000 59% 97%
difficulty or the causative agent may be NTM19.  However, whenever the 
results are positive the Mycobacterial load must have been sufficiently 
high.   Even though  PCR is  highly  sensitive,  expensive  and  laborious 
procedures cross contamination and false positive results should be taken 
into consideration. 
Several serological methods have been proposed both in the past 
decades  and more  recently  for  the  rapid diagnosis  of  TPE.   They are 
characterized  by  simplicity,  rapidity  of  technical  execution  as  well 
financial  viability  and automation.  The following reasons attracted the 
attention to establish the serological diagnosis.
1. Smear examination and in vitro culture of Mycobacteria yield 
low sensitivity as well as time consuming.
2. PCR claimed to be more sensitive but demands high level of 
skill, expensive set up and reagents.
3. All of the above methods demand sample collection from the 
site of infection which in many extra pulmonary situations may 
not be possible.
4. EPTB  is  difficult  to  diagnose  as  in  many  cases  clinical  & 
radiological findings are non-specific.
The  first  attempt  of  serodiagnosis  reported  by  Arloing  in  1898 
since then several studies have been carried out by using quite complex 
antigens such as whole bacteria,  culture filtrates,  bacterial  extracts and 
tuberculin’s or PPD.  The diagnostic value of these antigens have shown 
varying degree of success.
Enzyme  linked  Immunosorbant  assay  (ELISA)  technique  have 
been developed for the serodiagnosis of tuberculosis, which is a simple 
instrument with inexpensive reagents.  Cocito Et. Al., in 1991 reported a 
novel antigen, A60, which could be successfully used to detect IgG, IgA 
and IgM class of antibodies using an ELISA technique.
The A60 antigen based kit was selected for evaluation because it 
has been used widely in our country as evident with the Indian Literature 
(Kalantri Y)72.   Only few studies are available on the serodiagnosis of 
TPE.  The purpose  of  this  study is  to  evaluate  the  IgG,  IgA and IgM 
antibody response to A60 antigen complex in TPE.
Sensitivity and Specificity of ELISA diagnostic kits:
(IgG antibody measurement)
Antigen Sensitivity % Specificity %
38 KDa 49 – 89 98 – 100
30 KDa 62 – 78 97 – 100
16 KDa 24 – 71 97 – 99
LAM 26 – 81 92 – 100
A60 71 – 100 71 – 95
(source  :  Serodiagnosis  of  Tuberculosis  in  children.   S.  Mahadevan, 
JIMA issue vol.100,No.2, Feb 2002)
The wide variation in the sensitivity of various antigens is due to 
the fact the most of the antigens are genus specific.  There is wide spread 
sharing of  epitopes between various species.   Due to  lack of  a  single 
species  specific  antigen  various  studies  shows  variable  results.
In our study we have detected all the three antibodies using cut – 
off value given by the manufacture’s protocol.  We found out that IgG 
was positive in 57% of cases.  This is a correlation with the studies of 
Charpin Et. Al., 1990 who found out a sensitivity of 48% and specificity 
of 71% for IgG.  Caminero Et. Al., 1993 found out a sensitivity of 50 – 
55% and specificity of 100% for IgG.  Low sensitivity of IgG indicates 
that  most  of  the  patients  are  in  the  inactive  stage  of  the  disease.
IgM antibodies were positive in 61% of cases.  This indicates that 
most of the patients are in active stage of the disease.  In our study we 
have included 50% of the patients with pulmonary finding along with 
effusion.  High sensitivity of IgM indicates that effusion could be due  
to hypersensitivity reaction to tuberculin proteins.  In 1990, Charpin Et. 
Al., showed sensitivity of 76% and specificity of 98% for IgM.  In 2005, 
kalantri.Y. et.al., showed a sensitivity of 29 % and specificity of 96% for 
IgM. 
IgA was positive in 44 (42%) cases. Gupta et.al., in 1995 showed a 
sensitivity of 92% and specificity of 90 % for IgG and IgA. In 1999 kaur. 
J et.al., showed a sensitivity of 64 to 70% and specificity of 80 to 82 % 
for IgG and IgA . IgM and IgA were positive in 78(75%) cases. In most 
of the studies, the cutoff value is standardized to a low level but in our 
study we have followed the manufacture’s values. That could be one of 
the  reasons  for  the  low  sensitivity  of  IgA.   This  should  be  further 
evaluated.
 
We found out that PCR was only 70 % sensitive where as IgM and 
IgA antibodies  were  75%,  sensitive  so  in  peripheries  where  the  PCR 
facilities are not available, Serodiagnosis (ELISA) can be carried out as a 
supplementary  test  in  the  diagnosis  of  Tuberculous  pleural  effusion. 
Since this is only a pilot study, serology needs further evaluation.
FOLLOW UP OF PATIENTS:
All the patients were started on ATT regime recommended under 
RNTCP. The follow up of these patients after 6 months showed drastic 
improvement in clinical symptoms and follow up X-ray chest (PA) also 
showed improvement. All the patients were satisfactory except one HIV- 
seropositive  case,  who  died  after  8  months  of  treatment.  MDR  –TB 
patients were given second line drugs.
Conclusion
CONCLUSION
• We  have  successfully  established  a  panel  of  diagnostic  tests  for 
paucibacillary  tuberculous  plural  effusion  at  Coimbatore  Medical 
College, Coimbatore.
• Delay in diagnosis leads to sequelae as well as spread of infection to 
other organs.
• More than one diagnostic procedure is often needed for confirmation 
of TPE.
• Bacteriological, chemical (HPLC), molecular (PCR), and serological 
confirmation may aid in current diagnosis of TPE.
• Sputum smear examinations in TPE cases were useful only if there is 
concomitant pulmonary infiltrates.
• PCR is the rapid and sensitive test, which can be carried out where 
facilities are available.
• Drug susceptibility tests on culture positive cases will detect MDR – 
TB.
• Since  NTM  are  resistant  to  all  first  line  drugs,  the  principle  of 
therapy for NTM requires attention.
• Despite of large number of studies carried out over the past several 
years,  serology has found little place in the routine diagnosis of 
tuberculosis.   Sensitivity  and specificity  depends  on the  antigen 
used.
• This study shows that serodiagnosis is as equally sensitive as PCR. 
So  serology  can  be  carried  out  as  a  diagnostic  test  along  with 
clinical  evidence  to  diagnose  tuberculous  pleural  effusion  cases 
especially  in  peripheral  centers  where  PCR  facilities  are  not 
available.
Summary
SUMMARY
• Total  numbers  of  105  cases  of  clinically  diagnosed  TPE  were 
included in this study for demonstration of AFB both from sputum 
and pleural fluid and isolation of M. tuberculosis from pleural fluid.
• Among the 105 cases,  sputum smear for AFB was positive in 15 
cases,  pleural  fluid  smear  for  AFB  was  positive  in  four  cases. 
Culture was positive for M. tuberculosis in 19 cases and for NTM in 
two cases.  All the culture positive cases were confirmed by HPLC.  
• Four of the culture positive cases were found to harbor multi drug 
resistant  tuberculosis.   All  the  105  pleural  fluid  samples  were 
subjected to PCR which was positive in 73 cases.
• Sera collected from these patients were tested against A60 antigen 
complex.
• The study showed that IgM and IgA antibody response was good to 
A60 antigen complex.  IgM and IgA were positive in 78 cases.
• Screening of the study subjects for the presence of HIV infection, 
detected 3 cases were dually infected with TB and HIV.
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Appendix
 
APPENDIX
1.  Ziehl Neelsen Technique:
(a) Strong Carbol Fuchsin:
Basic Fuchsin :     10 gms.
Absolute alcohol :   100 ml.
Phenol :     50 gm.
D. Water :    900 ml.  
Dissolve basic Fuchsin in absolute alcohol, add D. Water to it and then 
add phenol.
(b) Acid Alcohol
Conc. Hcl. : 20 ml
Sodium Chloride : 20 gms.
D. Water :         500 ml.
Absolute Alcohol :       1500 ml.
Dissolve sodium chloride in distilled water, add acid slowly by the side of 
the conical flask, dissolve it and then add alcohol to it.  
(C) 1% Methylene Blue:
Methylene Blue : 1 μm 
D. Water :       100 ml.
Dissolve methylene blue in distilled water.
2.  Preparation of Middle Brook 7H9 Medium:
Salt Solution:
Ammonium sulphate :    0.50
Disodium Phosphate :    2.50
Monopotassium Phosphate :    1.00
Sodium Citrate :    0.10
Magnesium Sulphate :    0.25
Calcium Chloride :    0.0025
Zinc Sulphate :    0.001
Copper Sulphate :    0.001
Ferric Ammonium Citrate :    0.04
L. Glutamic Acid :    0.50
Pyridoxine :    0.01
Protein :    0.0005
Final pH :    6.6 ± 0.2.
Suspend 2.35 gm in 450 ml of D. Water.  Add 2 ml of glycerol and 
heat  if  necessary  to  dissolve  the  medium  completely.   Sterilize  by 
autoclaving at 15 Ibs pressure at 121˚c for 10 mts.  Cool to 45˚c or below 
and aseptically add 1 vial of middle brook ADC growth supplement.
ADC growth Supplement:
Bovine Albumin, Fraction V:    2.50   gm
Dextrose :    1.00    gm
Catalase :    0.0015 gm
D. Water :          50  ml.
Aseptically add 50 ml in 450 ml of sterile, middle brook 7H9 Broth Base. 
Mix well and pour into sterile screw capped tubes.
3.  Preparation of LJ Medium:
Mineral Salt Solution:
Monopotassium Phosphate  :    2.4 gms.
Magnesium Sulphate :    0.24.
Magnesium Citrate :    0.60.
Potato Starch (soluble) :    30.00.
L.  Asparagine :    3.60-.
Malachite Green :    0.40.
Suspend 9.31gms in 150 ml of D. Water containing 3.ml glycerol. 
Boil to dissolve the medium completely.  sterilize by autoclaving at 15 lbs 
pressure, 121˚c for 15 minutes.
Meanwhile  prepare  250ml  of  whole  egg  emulsion  collected 
aseptically.   Add  egg  emulsion  gently  to  base  mix  to  obtain  uniform 
mixture.  Distribute in sterile screw capped bottles. Arrange bottles in a 
slanted  position.
4.  HPLC:
Materials:
         KOH
1.  Saponification reagent               Reagent grade water.
Methanol
2.  Acidification reagent   Reagent grade water.
                        Conc. Hcl
                    KHco3
3.  KHco3 reagent                            Reagent grade water
                                                                            Methanol
4. Derivitization reagent.
5. Clarification reagent.
Sample Preparation:
A.  Cell harvesting procedure:
 
• Add 0.2ml of saponification reagent
• 1 - 2 loopful of growth on LJ medium.
• Vortex – 20 seconds.
B.  Saponification & extraction:
• Autoclave 121˚c – 15 psi – 1 hour.
• Add 2.0ml of chloroform.
• 1.5ml of acidification reagent.  Cap tightly.
• Vortex 20 seconds.
Allow the  layers  to separate  20  –  30  seconds.   Using glass  pasteur 
pipette, remove bottom layer (chloroform), containing mycolic acids and 
transfer to a new tube.  Evaporate chloroform in water bath at 85 - 105ºc.
C.  Derivitization to p. bromophenacyl esters:
• Add 0.1ml of KOH.
• Evaporate at 85 - 105˚ c.
• Cool the sample and add 1.0ml of chloroform followed by 50µl 
of Derivitization reagent. 
• Cap and vortex 30 sec.
• Heat at 85 - 105˚c for 20 minutes.
D.  Clarification by liquid – liquid extraction:
• Cool and add 1.0ml of clarification reagent. Vortex 20 sec.
• Remove the bottom layer (chloroform) and transfer to a new 
tube.
E. Completion and Storage:
Evaporate to dryness at 85 – 105˚c.  Cap tightly store at 4 – 6 °c in 
the dark.
5.  PCR 
A.  Experimental Procedure:
• Transfer one to two loopful of specimen to an eppendorf tube 
Containing 500µl TE buffer (pH 8.0).
• Heat 20mts at 80˚c to kill the organisms.
• Spin the sample in micro centrifuge for 2mts until a compact 
pellet forms.  Discard the supernatant and resuspended pellet 
in 500µl TE buffer by repeated pipetting.
• Add 50µl of (10mg/ml) lysozyme, mix and incubate 2hr at 37˚c.
• Add 70µl of 10% SDS and 6µl of (10mg/ml) proteinase K.
• Mix and incubate 10min at 65˚c.
• Add 100µl of 5M Nacl and mix thoroughly.
• Add 80µl of CTAB – Nacl solution.
• Mix thoroughly  and incubate for 10min at 65˚c.
• Add  an  approximately  equal  volume  of  chloroform/isoamyl 
alcohol mixture.
• Mix thoroughly, and spin in a micro centrifuge for 5min.
• Remove the aqueous supernatant to a fresh micro centrifuge 
tube.
• Add 600µl of isopropanol.
• Place at - 20˚c for 60minutes.
• Spin 15 min in a micro centrifuge at 10,000 rpm at 4˚c.
B.  Quantification of DNA:
When the DNA solution is of uniform viscosity, take 10µl 
and put it into a labeled 1.5ml tube and add 990µl sterile Milli Q 
water. Cap the tube, mix it and leave in fridge for 2 hours.  Use the 
quartz  cuvettes  and  TE  buffer  as  the  blank,  measure  the 
OD260nm and  OD280nm of  the  samples.   The  ratio  should  be 
greater than 1.75.
A solution with an OD260 of 1 contains 30µg of DNA per 
milliliter.   To  calculate  the  concentration  of  the  stock  DNA, 
multiply by the dilution factor (i.e., 100 = 300µg/ml).  To calculate 
the total amount of DNA, multiply by the total volume of the stock 
DNA (i.e., 0.4ml = 120µg).
C. PCR Protocols:
I. Reaction Volume
Typical  50µl  reaction  volume  given  below  will  be 
goodfor almost every PCR assay.  
Components Volume Final conc. In 
50µl
Milli Q Water -------- ------
10x Reaction buffer 5.0µl 1x
d NTP’s Mix (10mM) 1.0µl 200µM
Primer # 1 1.0µl 20 pM/Reaction
Primer # 2 1.0µl 20 pM/Reaction
Taq DNA Polymerase (IU/µl) 1.0µl 1U/Reaction
Template 10.0µl 100ng
• 10x Reaction buffer: 10mM Tris – Hcl, 50mM kcl, 1.5mM 
Mgcl2 Triton X 100  
• d NTP’s Mix : A mixture of d ATP, d GTP, d CTP and d 
TTP
• Primer # 1 : TB 4
• Primer # 2 : TB 5
Reconstitute  the  primer  with  TE  buffer  as  per 
requirements.
• Taq DNA Polymerase:  Ready to use.
II. Pipetting and DNA Template
Pipetting can be done under a laminar flow of sterile 
air and using aerosol – resistant pipette tip.
III. Thermocyclers and PCR vials.
While  using older  model  thermocyclers  (without  a 
heated  lid)  mineral  oil  is  necessary to  cover  the  reaction 
mixture.
D. Detection and analysis of PCR Product:
• Prepare 2% agarose gel using 1x electrophoresis buffer by 
melting it in a microwave oven.
• Add (1µl of stock/50ml) ethidium bromide to the gel when 
the gel reaches 50˚c .  Pour the mixture into the sealed gel 
casting platform.
• After  gel  has  hardened  remove  the  seal  from  the  gel  – 
casting  platform  and  remove  the  gel  comb.   Place  the 
platform  into  electrophoresis  tank  containing  sufficient 
electrophoresis buffer to cover the gel.
• Prepare  DNA  sample  with  loading  buffer  (18µl  of  PCR 
product + 2µl gel loading buffer) and load samples, marker 
DNA into the wells with a pipettor.
• Attach the lids and set the power pack.
• Turn off the power supply when the bromophenol blue dye 
from the  loading  buffer  has  migrated  a  distance  judged 
sufficient for separation of DNA fragments.
• Observe for the PCR product under Transilluminator.
6.  ELISA: (Anda TB)
Kit Components:
1. Sample diluent (light green).
2. Peroxidase – labeled anti human immunoglobulin in stabilized buffer 
(dark blue).
3. 10 – fold concentrated TMB (Tetramethyl benzidine).
4. TMB diluent citric acid – phosphate buffer containing  0.02% of H2O2.
5. Sulpheuric acid 0.5N (Stop solution - red).
6. IgG  and  IgA  references:   Negative  (yellow),  1U/ml  (white),  2U/ml 
(Purple), 4U/ml (Pink), 8U/ml (Bright Red) and 16U/ml (Light blue).
7. IgM references:  Negative (grey) and Positive (brown) limit.
8. 20. Fold concentrated wash buffer solution.
9. Break apart strips of wells coated with antigen A60 from M. bovis 
(BCG).
Reagent Preparation:
A. Washing solution:
Add  19  volumes  distilled  water  to  one  volume  of 
concentrated (20x) washing buffer.  In general 1litre is needed to 
wash one plate: add 950 ml D. water to 50 ml concentrated (20x) 
washing buffer.
B. TMB Work Solution:
Add 9 volumes of TMB diluent to one volume of conc. (10X) 
TMB solution.  
7.  ELISA (MICROLISA):
Kit Components:
1. Break  way  micro  wells  coated  with  HIV  –  1  &  HIV  –  2 
recombinant proteins packed in a pouch with dessicant.
2. Sample diluent.
3. Enzyme conjugate concentrate (100x) – Anti human IgG labeled 
with horse radish peroxidase with protein stabilizers.
4. Conjugate diluent (Buffer Containing Stabilizers).
5. Wash buffer Concentate (25x) PBS with surfactant.  Dilute 1 : 25 
with distilled water before use.
6. TMB concentrate (100x) – to be diluted before use.
7. Substrate (TMB diluent) – Buffer containing subtatie.
8. Negative Control  : Ready to use, normal human serum negative 
for HIV – 1, HIV – 2, HCV and HBs Ag and HCv,
9. Positive Control :   Ready  to  use,  inactivated  and  diluted 
human serum non reactive for HBs Ag and HCV, positive for HIV 
antibodies.
10. Stop Solution : Ready to use 2N sulpharic acid,.
Preparation of reagents:
A.  Sample Preparation: Micro well dilution.
• Pipette 100µl of sample diluent into the micro well.
• Add 10µl of serum sample of ensure thorough mixing.
B. Preparation of wash buffer:
Prepare at least 50ml (2ml concentrated buffer with 48ml water) 
of buffer for each Microlisa strip used.  Mix well before use.
C. Preparation of working conjugate:
Dilute conjugate concentrate 1: 100 in conjugate diluent.  Prepare 
a fresh dilution for each assay and mix thoroughly before use.
D. Preparation of Working substrate solution:
Dilute TMB concentrate 1: 100 in substrate, TMB diluent.
